Figure 2
Effect of apremilast on the mRNA expression of profibrotic markers in dermal fibroblasts. (a) SSc dermal fibroblasts (n = 5) were incubated with 1–10 μM apremilast for 48 h, and total mRNA was collected for assessment. No treatment group served as control. (b) Dermal fibroblasts from HC (n = 5) were incubated with 1–10 μM apremilast in the presence or absence of 10 ng/ml TGF-β1 for 48 h, and total mRNA was collected for assessment. Results were representative of at least two independent experiments. The data were expressed as the mean ± SD per group. *p < 0.05. n.s., not significant. TGF, transforming growth factor. See Fig. 1 for other abbreviations.
